PMID- 37781696
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231003
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event 
      Reporting System database.
PG  - 1249845
LID - 10.3389/fphar.2023.1249845 [doi]
LID - 1249845
AB  - Introduction: Epirubicin is widely used in many malignancies with good efficacy 
      and tolerability. However, investigations about adverse events (AEs) using 
      real-world information are still insufficient. Methods: We extracted 
      Epirubicin-related reports submitted between the first quarter of 2014 and first 
      quarter of 2023 from FAERS database. Four algorithms were utilized to evaluate 
      whether there was a significant correlation between Epirubicin and AEs. Results: 
      After de-duplicating, a total of 3919 cases were extracted. Among the 3919 cases, 
      we identified 1472 AEs, 253 of which were found to be adverse drug reactions 
      (ADRs) associated with Epirubicin. We analysed the occurrence of 
      Epirubicin-induced ADRs and found several unexpected significant ADRs, such as 
      hepatic artery stenosis, hepatic artery occlusion, intestinal atresia and so on. 
      Interestingly, we found gait apraxia, a neurological condition, was also 
      significantly associated with Epirubicin. To our knowledge, there haven't studies 
      that have reported an association between gait disorders and the usage of 
      epirubicin. Discussion: Our study identified new unexpected significant ADRs 
      related to Epirubicin, providing new perspectives to the clinical use of 
      Epirubicin.
CI  - Copyright (c) 2023 Wang, Guan, Wang, Shi, Zhu, Hua, Guo and Wang.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Urology, Second Hospital of Shanxi Medical University, Taiyuan, 
      China.
FAU - Guan, Xin
AU  - Guan X
AD  - Department of Cardiology, Shanxi Bethune Hospital, Shanxi Academy of Medical 
      Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 
      Taiyuan, China.
FAU - Wang, Shuang
AU  - Wang S
AD  - Department of Gastroenterology, Shanxi Bethune Hospital, Shanxi Academy of 
      Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical 
      University, Taiyuan, China.
FAU - Shi, Lipeng
AU  - Shi L
AD  - Department of General Surgery, Second Hospital of Shanxi Medical University, 
      Taiyuan, China.
FAU - Zhu, Yanfei
AU  - Zhu Y
AD  - Department of General Surgery, Second Hospital of Shanxi Medical University, 
      Taiyuan, China.
FAU - Hua, Pengbo
AU  - Hua P
AD  - Department of Urology, Second Hospital of Shanxi Medical University, Taiyuan, 
      China.
FAU - Guo, Qiang
AU  - Guo Q
AD  - Department of Urology, Second Hospital of Shanxi Medical University, Taiyuan, 
      China.
FAU - Wang, Jingqi
AU  - Wang J
AD  - Department of Urology, Second Hospital of Shanxi Medical University, Taiyuan, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230914
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10536159
OTO - NOTNLM
OT  - FDA Adverse Event Reporting System database
OT  - bayesian confidence propagation neural network (BCPNN)
OT  - empirical Bayes geometric mean (EBGM)
OT  - epirubicin
OT  - proportional reporting ratio (PRR)
OT  - reporting odds ratio (ROR)
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/10/02 06:42
MHDA- 2023/10/02 06:43
PMCR- 2023/09/14
CRDT- 2023/10/02 04:50
PHST- 2023/06/30 00:00 [received]
PHST- 2023/08/24 00:00 [accepted]
PHST- 2023/10/02 06:43 [medline]
PHST- 2023/10/02 06:42 [pubmed]
PHST- 2023/10/02 04:50 [entrez]
PHST- 2023/09/14 00:00 [pmc-release]
AID - 1249845 [pii]
AID - 10.3389/fphar.2023.1249845 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Sep 14;14:1249845. doi: 10.3389/fphar.2023.1249845. 
      eCollection 2023.